Biocon's Oral Insulin Fails To Meet Primary Endpoint
This article was originally published in The Pink Sheet Daily
Unfazed, company says stage set for partnering talks with global pharma.
You may also be interested in...
MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro
MUMBAI - Amidst a row over the safety and absorption profile of inhaled insulins, Biocon - which steadily advanced its orally-delivered insulin IN-105 into Phase III trials in India - has now filed an investigational new drug application with U.S. FDA
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.